Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. - Wikidata - wikimedia - TriplyDB

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

http://www.wikidata.org/entity/Q42795736

about

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts Clonal hematopoiesis in acquired aplastic anemia Dysregulation of ubiquitin ligases in cancer Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme.Clinical effect of point mutations in myelodysplastic syndromes Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Activating CBL mutations are associated with a distinct MDS/MPN phenotype.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions.Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase/Akt pathway.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia Differential expression of CHL1 gene during development of major human cancers.Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.Lnk constrains myeloproliferative diseases in mice.Protacs for treatment of cancer.Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma

P2860

Q24595117-4F502086-0CB0-4EB3-91E9-05CB267AD7F9 Q24621898-7AF3A851-7AB0-4D25-91BD-6257868D0ECA Q26779702-DBBD472E-7C0B-4CCB-99EE-5B5527FAE7AC Q26779960-899E3689-8785-46A7-80F3-FFD63D7B7723 Q26852269-D3625283-1B8B-4D38-9335-C3F7729425AC Q26853207-E5C953FD-25BE-483C-8B7F-E6168C66DB9D Q27676126-AEF11732-FBF2-44D1-A38D-844097D012A8 Q27677282-49647515-CAE4-4740-80CE-B98C5999CEEA Q27687464-0FE24829-A479-4341-A5A7-1F541E6FCE64 Q27851675-8652ECBB-DF27-4856-A11D-8CB1D15D17B9 Q28079733-308D5D15-2A36-49C2-AFEC-78744E1310CD Q28086796-5D5B633C-D963-4AA1-A217-DE998AFABA9A Q28307278-2DED4D67-1C2F-4ADC-91EB-81546B75D4D2 Q28307750-33688E36-5D64-46F6-A510-97CE598077F9 Q28397150-4FD19EA8-E02A-48F7-BEB3-A7CE3B277389 Q28535153-1625CE3A-F000-4EBD-8727-32241E465C00 Q28831057-7258230F-3B56-485B-BDEF-98AE67D0BEDB Q30009496-AD290870-037D-4C84-9376-43728D5425FE Q30156839-72AA9A7C-1AEC-42E0-B077-1488D7880152 Q33395996-BBB3AAE0-97EC-43D2-A14E-5135D28896D2 Q33402522-ACDBC55D-19D7-451A-9CF5-3F0095EF6656 Q33403530-455699A0-E96B-454B-9F0E-C04D7DCE2BF8 Q33413428-2F769289-6C13-484D-8A4E-ABBD661DF00F Q33528991-BE804264-28FE-49F9-8E73-4E94FB81C446 Q33558105-061E0F27-022B-46E2-A11F-4E98D7501E33 Q33615619-A0597150-89C3-44F2-9DC3-18ACEA2F67E8 Q33647411-0E25C94C-2355-4BA5-A56E-DF290C1A3CFE Q33701852-8E75B623-C3FE-411A-A3C5-6CEB5A0359FF Q33722741-6A5F2C7F-BCA0-404A-A0B6-797E0884FB70 Q33762830-988C9221-6529-4C66-9DF5-193560531DA7 Q33770092-2B7E4266-BBF2-4BAB-94F5-09F91FF6107B Q33774488-2E5D0BBC-F828-4F67-BDAD-3D0513405F2C Q33796333-10D758CA-4F83-4BF9-B210-48EF6C97AC5A Q33796552-2314B0F0-1D5E-4CFF-A804-9F50B8B2FD83 Q33847826-CA210D79-C4D2-4DB2-8249-93EC97469588 Q33870784-8FD10EAB-01E6-48FE-B83A-CCA6B6577F78 Q33882944-2F3E418D-3529-4FA9-B324-BBB10A227C31 Q33896048-40E5429B-F375-44FD-9F85-181012CC4FA1 Q33925815-DE8B2955-E4A3-45DC-95AA-0EFA76094873 Q33977014-B5199557-CE6F-404F-BC77-575B28DA4504

P2860

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

http://www.wikidata.org/entity/Q42795736

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@en

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@nl

type

label

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@en

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@nl

prefLabel

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@en

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@nl

P1433

Q42795736-F14B8796-A925-4A2E-9C69-E0DE0847A0A6

P1476

Q42795736-EE47276D-E3B5-4C6C-986E-9F37D5CEBB57

P2093

Q42795736-04F9B3F6-8289-4F55-B397-2665050FC465

Q42795736-06011E4A-117A-45CA-8ED1-E440FCF992B9

Q42795736-17C1FEF9-814C-4A7C-AE5B-45794F2D95C0

Q42795736-22AE360E-0A72-4A42-BC61-A160EFFA3B6E

Q42795736-36FAC9D0-ACFD-438A-956C-E59BE93C122F

Q42795736-3BCD208F-4899-4604-A59A-111C77D9F753

Q42795736-3E446DDD-8049-4E7E-8D10-1E15EF0FC661

Q42795736-44FAADB8-394F-4277-803C-FE78CBC74A28

Q42795736-58E6B9F1-5B57-4F21-B9E7-81163A613F67

Q42795736-5D04AA57-C53A-4452-AB03-96EE56364473

P2860

Q42795736-5C9EA565-6A2B-442D-A25A-C5CF4F147BCF

P2888

Q42795736-7E51FE6E-3B25-44F4-B8FD-D51AE608BAFF

P304

Q42795736-FC68A6B6-2923-475E-9FB8-E0141FDD6D17

P31

Q42795736-E44F6552-7796-44F8-B4F5-D12F2CF90ECA

P356

Q42795736-4E1AF0AA-2D05-4117-B3C6-720A261CBE8B

P407

Q42795736-048D2B59-E9FF-4576-B440-C05022098651

P433

Q42795736-BA310EC6-7374-4882-90BD-CE58EC1727AE

P478

Q42795736-95B93BD7-9E98-43E0-AA14-371271AA9FDA

P50

Q42795736-52CF592D-9DF1-4BA7-835E-191B2D27023B

Q42795736-5B02AC18-3DB8-4E66-8E63-09091B7C831D

Q42795736-ADF00223-DC40-4322-A0B8-9B3223C7D2D9

P577

Q42795736-3C0A42B5-83A4-4A43-A688-895E0DC68CC8

P698

Q42795736-E695DBC0-93F7-424F-BB9E-F4B91DD26E28

P356

P1433

P1476

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

@en

P2093

Azusa Tamura

http://www.w3.org/2001/XMLSchema#string

H Phillip Koeffler

http://www.w3.org/2001/XMLSchema#string

Hideaki Oda

http://www.w3.org/2001/XMLSchema#string

Hiraku Mori

http://www.w3.org/2001/XMLSchema#string

Hiroaki Honda

http://www.w3.org/2001/XMLSchema#string

Hiromitsu Nakauchi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Harada

http://www.w3.org/2001/XMLSchema#string

Hisamaru Hirai

http://www.w3.org/2001/XMLSchema#string

Junko Takita

http://www.w3.org/2001/XMLSchema#string

Keiki Kumano

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice

P2888

P304

904-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE08240

http://www.w3.org/2001/XMLSchema#string

P407

P433

7257

http://www.w3.org/2001/XMLSchema#string

P478

460

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19620960

http://www.w3.org/2001/XMLSchema#string